Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01254890 · BASELINE

Baseline characteristics

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome · Source last updated 2016-05-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      3
    2. group Id
      BG001
      value
      57
    3. group Id
      BG002
      value
      60
    units
    Participants
groups
  1. description
    Azacitidine (AZA) 75 mg/m\^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days and Sorafenib starting dose 200 mg orally twice a day for 28 Day cycle.
    id
    BG000
    title
    Phase I: Azacitidine + Sorafenib
  2. description
    Azacitidine (AZA) 75 mg/m\^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days and Sorafenib 400 mg orally twice a day for 28 Day cycle.
    id
    BG001
    title
    Phase II: Azacitidine + 400 Sorafenib
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          40
          upper Limit
          87
          value
          73
        2. group Id
          BG001
          lower Limit
          20
          upper Limit
          81
          value
          64
        3. group Id
          BG002
          lower Limit
          20
          upper Limit
          87
          value
          64
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
        2. group Id
          BG001
          value
          27
        3. group Id
          BG002
          value
          28
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          2
        2. group Id
          BG001
          value
          30
        3. group Id
          BG002
          value
          32
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          3
        2. group Id
          BG001
          value
          57
        3. group Id
          BG002
          value
          60
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      3
    2. group Id
      BG001
      value
      57
    3. group Id
      BG002
      value
      60
    units
    Participants
groups
  1. description
    Azacitidine (AZA) 75 mg/m\^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days and Sorafenib starting dose 200 mg orally twice a day for 28 Day cycle.
    id
    BG000
    title
    Phase I: Azacitidine + Sorafenib
  2. description
    Azacitidine (AZA) 75 mg/m\^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days and Sorafenib 400 mg orally twice a day for 28 Day cycle.
    id
    BG001
    title
    Phase II: Azacitidine + 400 Sorafenib
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          40
          upper Limit
          87
          value
          73
        2. group Id
          BG001
          lower Limit
          20
          upper Limit
          81
          value
          64
        3. group Id
          BG002
          lower Limit
          20
          upper Limit
          87
          value
          64
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
        2. group Id
          BG001
          value
          27
        3. group Id
          BG002
          value
          28
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          2
        2. group Id
          BG001
          value
          30
        3. group Id
          BG002
          value
          32
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          3
        2. group Id
          BG001
          value
          57
        3. group Id
          BG002
          value
          60
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice